^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Glioma

Related cancers:
10h
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
P1, N=29, Terminated, Pyramid Biosciences | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
13h
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors (clinicaltrials.gov)
P1, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type
|
Tagrisso (osimertinib) • Tepmetko (tepotinib)
13h
CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro. (PubMed, BMC Cancer)
Bestatin treatment reduced proliferation, migration and colony formation of glioma cells in a CD13-dependent manner while apoptosis was increased. In summary, CD13 has an impact on glioma patient survival and is important for the main function of specific glioma cells.
Preclinical • Journal
|
ANPEP (Alanyl Aminopeptidase, Membrane)
|
ubenimex (DFP-14323)
15h
NOP14 as a Potential Predictor of Adult-Type Diffuse Glioma Prognosis and Immunotherapy, is Related to Cell Migration, Proliferation, and CD8+T Cell Infiltration. (PubMed, Front Biosci (Landmark Ed))
NOP14 holds great promise as a candidate biomarker for detecting prognostic, molecular, and immune signatures of adult-type diffuse glioma.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
19h
Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma. (PubMed, Biochem Genet)
In general, our study classified glioma patients into distinct subgroups based on CAF markers, which will facilitate the development of individualized therapy. We also provided insights into the role of the CRS in predicting the response to ICB and chemotherapy in glioma patients.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
24h
Epidemiology and Outcomes of Neurofibromatosis Type 1 (NF-1): Multicenter Tertiary Experience. (PubMed, J Multidiscip Healthc)
Furthermore, the identification of these attributes will facilitate an expeditious and accurate diagnosis. Hence, the implementation of intervention during its nascent phase may result in a more advantageous consequence.
Journal
|
NF1 (Neurofibromin 1)
1d
Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients. (PubMed, Heliyon)
Additionally, PCOLCE may exert its roles via several immune-related biological processes or pathways, such as leukocyte migration, activation of T cells, adaptive immune response, neutrophil-mediated immunity, NF-κB, and TNF signaling pathways. In conclusion, PCOLCE may be a new immune-related gene and regulate tumor development through immunological pathways.
Journal
|
CD4 (CD4 Molecule)
1d
Metal ion stimulation-related gene signatures correlate with clinical and immunologic characteristics of glioma. (PubMed, Heliyon)
The gene features associated with metal ion stimulation are related to the clinical and immune characteristics of transgenic patients. XGboost/LightGBM Kmeans has a higher classification prediction accuracy in predicting glioma grades compared to using purely supervised classification techniques.
Journal • Gene Signature
|
CDK1 (Cyclin-dependent kinase 1)
1d
Neuropathology and epilepsy surgery - 2024 update. (PubMed, Free Neuropathol)
Finally, I will highlight the ongoing discussion addressing commonalities between temporal lobe epilepsy and Alzheimer's disease, the impact of adult neurogenesis and gliogenesis for the initiation and progression of temporal lobe seizures in the human brain as well as the immunopathogenesis of glutamic acid decarboxylase antibody associated temporal lobe epilepsy as a meaningful disease entity. This review will update the reader on some of these fascinating publications from 2022 and 2023 which were selected carefully, yet subjectively, by the author.
Journal • Surgery
|
BRAF (B-raf proto-oncogene) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SLC35A2 (Solute Carrier Family 35 Member A2)
1d
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (clinicaltrials.gov)
P1, N=230, Recruiting, Nested Therapeutics, Inc | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene)
1d
AB-218-IIT-201: A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Melbourne Health | Recruiting --> Active, not recruiting
Enrollment closed
|
erbumine (LY3295668) • safusidenib (AB-218)
1d
Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma (clinicaltrials.gov)
P1, N=30, Recruiting, Nader Sanai | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CASP3 (Caspase 3)
|
ALA sonodynamic therapy
1d
Ivy 2020-10: AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients (clinicaltrials.gov)
P1, N=37, Recruiting, Nader Sanai | Trial primary completion date: Jan 2024 --> Jul 2024
Trial primary completion date
|
AZD1390
1d
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients (clinicaltrials.gov)
P1, N=48, Active, not recruiting, Nader Sanai | Trial completion date: Jan 2024 --> Jan 2025
Trial completion date
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
CDKN2A deletion • CCND1 amplification • CDK4 amplification
|
Kisqali (ribociclib)
1d
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (clinicaltrials.gov)
P1, N=15, Not yet recruiting, Nationwide Children's Hospital
New P1 trial
|
ALK fusion • ROS1 fusion
|
carboplatin • Lorbrena (lorlatinib) • cyclophosphamide
1d
Proton Radiation Therapy for Gliomas (clinicaltrials.gov)
P=N/A, N=63, Active, not recruiting, Massachusetts General Hospital | Unknown status --> Active, not recruiting | Phase classification: P2 --> PN/A | Trial completion date: Aug 2022 --> Nov 2025 | Trial primary completion date: Aug 2021 --> May 2025
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
1d
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (clinicaltrials.gov)
P1, N=50, Recruiting, Nader Sanai | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
CDK4 amplification
|
Verzenio (abemaciclib) • temuterkib (LY3214996)
1d
Preclinical • Journal
|
CDH1 (Cadherin 1) • SMO (Smoothened Frizzled Class Receptor) • GLI1 (GLI Family Zinc Finger 1) • MEG3 (Maternally Expressed 3)
2d
STING is significantly increased in high-grade glioma with high risk of recurrence. (PubMed, Oncoimmunology)
Interestingly, STING inhibitors and agonists both suppress the growth of HGG cells, regardless of their STING levels and STING pathway activity, whereas RAD51 inhibitor B02 is found to exclusively sensitize HGG cells with high expression of STING to temozolomide in vitro and in vivo. Overall, findings in the study not only reveal that ATRX is closely correlated with STING to drive the relapse of HGG, but also provide a STING-guided combined strategy to treat patients with aggressive gliomas. Translation of these findings will ultimately improve the outcomes for ATRX and IDH1 genomically stratified subgroups in HGG.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency) • ATRX (ATRX Chromatin Remodeler) • RAD51 (RAD51 Homolog A) • STING (stimulator of interferon response cGAMP interactor 1)
|
temozolomide
2d
Dysregulation of LINC00324 promotes poor prognosis in patients with glioma. (PubMed, PLoS One)
Indeed, our results confirm that the LINC00324 signature holds promise as a prognostic predictor in glioma patients. This finding opens up new possibilities for understanding the disease and may offer valuable insights for the development of targeted therapies.
Journal • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD40 (CD40 Molecule) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • ITGB2 (Integrin Subunit Beta 2)
2d
A dynamic study of VEGF-A siDOX-EVs trafficking through the in-vitro insert co-culture blood-brain barrier model by digital holographic microscopy. (PubMed, Front Oncol)
Moreover, our results indicated that the VEGF-A siDOX-EVs insert cytotoxic impact on the cells of the bottom of the culture plate. folate-conjugation on the surface of EVs improves their trafficking through the blood-brain barrier and by using digital holographic microscopy analysis, we could directly assess the morphometric changes of the blood-brain barrier cells for pharmacological purposes as an easy, label-free, and real-time analysis.
Preclinical • Journal
|
VEGFA (Vascular endothelial growth factor A)
2d
Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth. (PubMed, Acta Neuropathol Commun)
When controlled for genotype, the close association between glioma aggressiveness and patient age has very few proposed biological explanations. Our findings indicate that age-associated increases in cerebral vascular insufficiency and associated regional chronic cerebral hypoxia may contribute to this phenomenon.
Journal
|
FGF1 (Fibroblast Growth Factor 1)
2d
New P3 trial
|
albumin-bound paclitaxel
2d
OU-SCC-PI-4G: PARP Inhibition for Gliomas (PI-4G or π4g) (clinicaltrials.gov)
P2, N=15, Terminated, University of Oklahoma | N=45 --> 15 | Trial completion date: Nov 2024 --> Feb 2024 | Active, not recruiting --> Terminated; Funder terminated funding.
Enrollment change • Trial completion date • Trial termination
|
Myriad myChoice® CDx
|
Zejula (niraparib)
3d
Bergaptol inhibits glioma cell proliferation and induces apoptosis via STAT3/Bcl-2 pathway. (PubMed, Anticancer Drugs)
In addition, bergaptol administration also significantly inhibited the STAT3/Bcl-2 pathway of tumour tissue in vivo. Overall, we found that bergaptol could effectively play an antiglioma role by inhibiting STAT3/Bcl-2 pathway, suggesting the potential efficacy of bergaptol in treating glioma.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)
3d
NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway. (PubMed, J Cell Mol Med)
The nude mice xenograft model showed NPS-2143 could suppress glioma growth in vivo. In conclusion, NPS-2143 can suppress the glioma progression by inhibiting autophagy.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASR (Calcium Sensing Receptor)
3d
Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation. (PubMed, J Inflamm Res)
Furthermore, our findings confirmed a positive correlation between COTL1 expression, CD8, and PD-L1 in LGG, as well as an association of high COTL1 expression with decreased patient survival in LGG. Based on these compelling findings, COTL1 may hold significant clinical implications for the development of novel cancer therapies and serve as a potential target for tumors associated with immunotherapy in the future.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • HRD • CD8 expression
3d
CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis. (PubMed, J Inflamm Res)
Subtype-specific patterns are formed by the various inflammatory CSF parameters in NMDAR-E, LGI1-E, and GABABR-E, and their correlation with disease severity, age, and disease duration. CSF inflammatory characteristics associated with MCP-1, IL-10, IL-1β, and IL-4 may be potential immunopathogeneses targeting markers for these AE subtypes.
Journal
|
IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
3d
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma (clinicaltrials.gov)
P1, N=30, Recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2025 --> Dec 2024
Trial completion date
4d
Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro. (PubMed, J Control Release)
DC-EVs loaded with VEGF-A siRNA and Doxorubicin were more potent than BV alone as a multi-disciplinary strategy that combats glioma growth by cytotoxic impacts of DOX and inhibits angiogenesis by VEGF-A siRNAs with excess immunologic benefits from DC-EVs. This next-generation anti-angiogenic agent normalizes tumor vessel density rather than extensively eliminating tumor vessels causing hypoxia and mesenchymal transition.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • VEGFA (Vascular endothelial growth factor A) • VIM (Vimentin)
|
VIM expression
|
doxorubicin hydrochloride
4d
Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities. (PubMed, Int J Biol Macromol)
The novel functionalized nanocarrier approach in conjunction with biological and chemical modification offers an intriguing potential to address challenges associated with the naked siRNA and efficiently silence STAT3, coffilin-1, EGFR, VEGF, SMO, MGMT, HAO-1, GPX-4, TfR, LDLR and galectin-1 genes in GBM tumor. This review highlights the nanoengineered siRNA carriers, their recent advancements, future perspectives, and strategies to overcome the systemic siRNA delivery challenges for glioma treatment.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • LGALS1 (Galectin 1) • GPX4 (Glutathione Peroxidase 4)
4d
Diterpenoid honatisine overcomes temozolomide resistance in glioblastoma by inducing mitonuclear protein imbalance through disruption of TFAM-mediated mtDNA transcription. (PubMed, Phytomedicine)
In summary, our data provide new insights into the therapeutic mechanisms underlying honatisine's selective inducetion of apoptosis and its ability to overcome chemotherapy resistance in GBM. These actions are mediated through the disruption of mitochondrial proteostasis and function, achieved by the inhibition of TFAM-mediated mtDNA transcription. This study highlights honatisine's potential as a promising agent for glioblastoma therapy, underscoring the need for further exploration and investigation.
Journal
|
TFAM (Transcription Factor A, Mitochondrial)
|
temozolomide
4d
Reactivating PTEN to impair glioma stem cells by inhibiting cytosolic iron-sulfur assembly. (PubMed, Sci Transl Med)
Functionally, inhibiting PTEN C211 succination by reexpressing a PTEN C211S mutant, depleting ADSL by shRNAs, or consuming fumarate by the US Food and Drug Administration-approved prescription drug N-acetylcysteine (NAC) impaired GSC maintenance. Reexpressing PTEN C211S or treating with NAC sensitized GSC-derived brain tumors to temozolomide and irradiation, the standard-of-care treatments for patients with glioblastoma, by slowing CIA machinery-mediated DNA damage repair. These findings reveal an immediately practicable strategy to target GSCs to treat glioblastoma by combination therapy with repurposed NAC.
Journal
|
PTEN (Phosphatase and tensin homolog) • MMS19 (MMS19 Homolog)
|
PTEN expression
|
temozolomide
4d
Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma. (PubMed, PLoS One)
Together, these results implicate the hydrolysis function of endolysosomes in shaping the immunosuppressive microenvironment of GBM. We propose that targeting endolysosomes, in addition to its detrimental effects on tumor cells, can be leveraged for modulating immunosuppression to render GBMs more amenable to immunotherapies.
Journal • IO biomarker
|
CTSS (Cathepsin S)
4d
CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer. (PubMed, Sci Rep)
These findings establish CDK12 as a significant biological indicator of cancer diagnosis, prognosis, and immunotherapeutic targeting. Early surveillance and employment of CDK12 inhibitors, along with concomitant immunotherapy interventions, may enhance the clinical outcomes of cancer patients.
Journal • IO biomarker • Pan tumor • Immunomodulating
|
CDK12 (Cyclin dependent kinase 12)
|
CDK12 mutation
4d
Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium. (PubMed, BMJ Open)
In newly diagnosed patients, this comprises chemoradiation (oral temozolomide 90 mg/m2 daily+radiotherapy 54 Gy in 1.8 Gy fractions) followed by three induction WT1/DC vaccines (8-10×106 cells/vaccine) given on a weekly basis and a chemoimmunotherapy booster phase consisting of six 28-day cycles of oral temozolomide (150-200 mg/m2 on days 1-5) and a WT1/DC vaccine on day 21...Results of the clinical trial will be shared through publication in a peer-reviewed journal and presentations at conferences. NCT04911621.
P1/2 data • Journal
|
WT1 (WT1 Transcription Factor)
|
temozolomide
4d
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]. (PubMed, BMC Neurol)
The following systematic review details a comprehensive investigation of the current literature and highlights several potential key CpG sites that demonstrate significant association with OS, PFS, and MGMT expression. However, the relationship between extent of MGMT promoter methylation and survival may be non-linear and could be influenced by potential CpG hotspots, the extent of methylation at each CpG site, and MGMT enhancer methylation status. There were several limitations within the studies such as smaller sample sizes, variance between methylation testing methods, and differences in the various statistical methods to test for association to outcome. Further studies of high impact CpG sites in MGMT methylation is warranted.
Review • Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
MGMT promoter methylation • MGMT expression
5d
FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation. (PubMed, Cell Death Discov)
In addition, our data confirm that there are positive correlations among FBXO22, HIF-1α, and VEGFA expression, and there is a negative correlation between FBXO22 and VHL protein expression in glioma patients. Our study strongly indicates that FBXO22 is a promising diagnostic marker and therapeutic target for glioma patients.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor)
|
HIF1A expression • VEGFA expression
5d
Multi-scale feature fusion for prediction of IDH1 mutations in glioma histopathological images. (PubMed, Comput Methods Programs Biomed)
Our method can be deployed in medical aid systems at very low cost, serving as a diagnostic or prognostic tool for glioma patients in medically underserved areas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
6d
The Mechanism of miR-29 in Bladder Cancer Released by Exosomes into Brain Microglia to Promote M2 Polarization and Angiogenesis in Brain Metastasis of Bladder Cancer. (PubMed, Altern Ther Health Med)
Bladder cancer cells T24 were transfected with miR-29 NC, mimic, or neferine and divided into miR-29-NC group, miR-29-mimic group, miR-29-NC-neferine group, and miR-29-mimic-neferine group...In vivo experiments demonstrated that miR-29 could promote the cell volume of bladder cancer cells and increase the number of blood vessels in bladder cancer cells, while neferine could inhibit the above effects. miR-29 can regulate PI3K/AMPK/PGC-1α/PPAR-γ signaling in microglial cells, promote their polarization to M2, and ultimately promote neovascularization in bladder cancer.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MRC1 (Mannose Receptor C-Type 1) • MIR29A (MicroRNA 29a)
|
HIF1A expression • AMPK expression
6d
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy. (PubMed, Discov Oncol)
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-based therapy was established and internally validated. It could serve as a reference tool for clinicians to assess the extent the patients may benefit from bevacizumab and stratify their treatment response.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR wild-type
|
Avastin (bevacizumab)
6d
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation (clinicaltrials.gov)
P1, N=95, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Dec 2023 --> Mar 2024
Trial completion date • Metastases
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 mutation • IDH2 mutation
|
vorasidenib (S95032)